Study S002347

SURE ITALY: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04094415
Acronym: SURE ITALY
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 581
Start: 2019-10-28
Primary completion: 2021-07-28
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1233-2023

Registered primary outcomes

Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]
Change in HbA1c (measured in mmol/mol) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021562	Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study. Napoli R, Diabetes, obesity & metabolism	2023	Nonrandomized study	PMID 36789682 DOI	registry reference BACKGROUND:36789682